Southeast Asset Advisors LLC Buys 6,167 Shares of Johnson & Johnson $JNJ

Southeast Asset Advisors LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 14.7% during the third quarter, Holdings Channel.com reports. The firm owned 48,154 shares of the company’s stock after purchasing an additional 6,167 shares during the quarter. Johnson & Johnson makes up about 1.0% of Southeast Asset Advisors LLC’s investment portfolio, making the stock its 17th biggest position. Southeast Asset Advisors LLC’s holdings in Johnson & Johnson were worth $8,929,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Johnson & Johnson by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock worth $36,209,060,000 after acquiring an additional 3,085,180 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Johnson & Johnson by 2.1% during the second quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock worth $9,227,988,000 after purchasing an additional 1,225,676 shares in the last quarter. Norges Bank purchased a new stake in shares of Johnson & Johnson during the 2nd quarter valued at $4,877,174,000. Bank of New York Mellon Corp boosted its position in shares of Johnson & Johnson by 3.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 24,637,649 shares of the company’s stock worth $4,568,313,000 after purchasing an additional 835,146 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Johnson & Johnson by 0.3% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 18,951,337 shares of the company’s stock valued at $2,894,979,000 after buying an additional 52,074 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Jim Cramer publicly praised J&J on-air, calling the company “amazing,” which can boost retail investor interest and provide short-term support for the stock. Johnson & Johnson (JNJ) Is Amazing, Says Jim Cramer
• Neutral Sentiment: Wall Street Zen cut JNJ to a Hold, signaling reduced upside conviction from at least one boutique research provider; that can temper buying enthusiasm but is not a major institutional downgrade. Johnson & Johnson (NYSE:JNJ) Cut to Hold at Wall Street Zen
• Negative Sentiment: A Pennsylvania jury found J&J liable in a talc/ovarian-cancer case and ordered $250,000 in damages to the family of Gayle Emerson — a reminder that ongoing talc litigation continues to create legal costs, uncertainty and headline risk for the company. Jury: Johnson & Johnson Liable in Case Linking Baby Powder to Cancer

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on JNJ shares. Sanford C. Bernstein raised their price target on Johnson & Johnson from $208.00 to $225.00 and gave the stock a “market perform” rating in a report on Friday, January 23rd. Wall Street Zen downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday. UBS Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Monday, January 5th. Daiwa Securities Group boosted their price objective on shares of Johnson & Johnson from $203.00 to $237.00 and gave the company an “outperform” rating in a report on Thursday, January 29th. Finally, Wells Fargo & Company upped their target price on Johnson & Johnson from $230.00 to $240.00 and gave the company an “overweight” rating in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $233.73.

Johnson & Johnson Stock Down 0.5%

JNJ stock opened at $243.37 on Monday. The company has a market capitalization of $586.51 billion, a P/E ratio of 22.02, a price-to-earnings-growth ratio of 2.36 and a beta of 0.35. The firm’s fifty day simple moving average is $217.25 and its 200-day simple moving average is $196.79. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $246.35. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The company had revenue of $24.28 billion for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 47.06%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.